Seth Lederman - 25 Mar 2022 Form 4 Insider Report for Tonix Pharmaceuticals Holding Corp. (TNXP)

Role
Chief Executive Officer, Director
Signature
/s/ Seth Lederman
Issuer symbol
TNXP
Transactions as of
25 Mar 2022
Net transactions value
+$24,500
Form type
4
Filing time
28 Mar 2022, 08:00:29 UTC
Previous filing
17 Feb 2022
Next filing
01 Jul 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TNXP Common Stock, $0.001 par value Purchase $24,500 +100,000 +821% $0.2450 112,177 25 Mar 2022 Direct
holding TNXP Common Stock, $0.001 par value 135,000 25 Mar 2022 By 401(k) plan
holding TNXP Common Stock, $0.001 par value 459 25 Mar 2022 By IRA Account
holding TNXP Common Stock, $0.001 par value 31 25 Mar 2022 By spouse
holding TNXP Common Stock, $0.001 par value 30 25 Mar 2022 By Leder Laboratories, Inc. F1
holding TNXP Common Stock, $0.001 par value 30 25 Mar 2022 By Starling Pharmaceuticals, Inc. F1
holding TNXP Common Stock, $0.001 par value 205 25 Mar 2022 By Lederman & Co., LLC F1
holding TNXP Common Stock, $0.001 par value 33 25 Mar 2022 By L&L Technologies, LLC F1
holding TNXP Common Stock, $0.001 par value 59 25 Mar 2022 By Targent Pharmaceuticals, LLC F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reporting person may be deemed to be a control person of this entity.